Cited 13 times in
Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이혜원 | - |
dc.date.accessioned | 2021-09-29T01:33:49Z | - |
dc.date.available | 2021-09-29T01:33:49Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184430 | - |
dc.description.abstract | Background/aims: Serum fibrosis scores comprised of common laboratory tests have high utility to assess severity of liver fibrosis. We aimed to derive and validate a hepatocellular carcinoma (HCC) risk score based on serum fibrosis scores to predict HCC in treatment-naïve chronic hepatitis B (CHB) patients. Methods: Fifteen thousand one hundred eighty-seven treatment-naïve adult CHB patients were identified to form the training cohort in this retrospective study. Individual fibrosis score was included to construct a new HCC prediction score. The score was externally validated in an independent treatment-naïve Korean CHB cohort. Results: 180/15,187 patients (1.2%) in training cohort and 47/4,286 patients (1.1%) in validation cohort developed HCC during a mean follow-up of 52 and 50 months, respectively. The newly developed HCC risk score, Liang score, is composed of gender, age, hepatitis B virus DNA, fibrosis-4 (FIB-4) index, and ranges from 0 to 22. Area under the time-dependent receiver operating characteristic curve of Liang score was 0.79 (95% confidence interval, 0.70-0.89). A cutoff value of nine provided an extremely high negative predictive value of 99.9% and high sensitivity of 90.0% at 5 years in the validation cohort. Patients with Liang score ≤9 had HCC incidence <0.2% per year in both training and validation cohorts, in whom HCC surveillance might be exempted. Conclusion: A novel HCC risk score, Liang score, based on FIB-4 index, is applicable and accurate to identify treatment-naïve CHB patients with very low risk of HCC to be exempted from HCC surveillance. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Association for the Study of the Liver | - |
dc.relation.isPartOf | CLINICAL AND MOLECULAR HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Lilian Yan Liang | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Vincent Wai-Sun Wong | - |
dc.contributor.googleauthor | Terry Cheuk-Fung Yip | - |
dc.contributor.googleauthor | Yee-Kit Tse | - |
dc.contributor.googleauthor | Vicki Wing-Ki Hui | - |
dc.contributor.googleauthor | Grace Chung-Yan Lui | - |
dc.contributor.googleauthor | Henry Lik-Yuen Chan | - |
dc.contributor.googleauthor | Grace Lai-Hung Wong | - |
dc.identifier.doi | 10.3350/cmh.2020.0333 | - |
dc.contributor.localId | A03318 | - |
dc.relation.journalcode | J00557 | - |
dc.identifier.eissn | 2287-285X | - |
dc.identifier.pmid | 33631920 | - |
dc.subject.keyword | Carcinoma, Hepatocellular | - |
dc.subject.keyword | Fibrosis | - |
dc.subject.keyword | Hepatitis B, Chronic | - |
dc.subject.keyword | Surveillance | - |
dc.contributor.alternativeName | Lee, Hye Won | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.citation.volume | 27 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 499 | - |
dc.citation.endPage | 509 | - |
dc.identifier.bibliographicCitation | CLINICAL AND MOLECULAR HEPATOLOGY, Vol.27(3) : 499-509, 2021-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.